Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants
Oksana Penezina(Immunetics (United States)), Isaac R. Rodriguez‐Chavez(National Institutes of Health), Andrew Levin(Harvard University), N. Krueger(Immunetics (United States)), Eric Hunter(Emory University), David E. Clapham(Janelia Research Campus), Keith Higgins(Global Solutions for Infectious Diseases), Michael P. Busch(Vitalant), Robert J. O’Connell(Walter Reed Army Institute of Research), V. A. Kovalenko(Immunetics (United States)), David Crane(Immunetics (United States)), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jérôme H. Kim(International Vaccine Institute), Said Aboud(Muhimbili University of Health and Allied Sciences)
Cited by 16
Related Papers
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
|New England Journal of Medicine|2009|3k
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
A Unified Nomenclature for the Superfamily of TRP Cation Channels
|Molecular Cell|2002|679
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|New England Journal of Medicine|2013|586